The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.
Stereoselective Formation of Carbon−Carbon Bonds via S<sub>N</sub>2-Displacement: Synthesis of Substituted Cycloalkyl[<i>b</i>]indoles
作者:Michael C. Hillier、Jean-François Marcoux、Dalian Zhao、Edward J. J. Grabowski、Arlene E. McKeown、Richard D. Tillyer
DOI:10.1021/jo051146p
日期:2005.10.1
A general asymmetric synthesis of substituted cycloalkyl[b]indoles has been accomplished. The key features of this approach are (1) the utilization of a Japp−Klingemann condensation/Fischer cyclization to prepare cycloalkyl[b]indolones, (2) the asymmetric boranereduction of these heterocyclic ketones with (S)-OAB to obtain enantiomerically pure alcohols, and (3) the stereoselective SN2-displacement
已经完成了取代的环烷基[ b ]吲哚的一般不对称合成。该方法的关键特征是:(1)利用Japp-Klingemann缩合/菲舍尔环化反应制备环烷基[ b ]吲哚酮,(2)用(S)-OAB将这些杂环酮不对称还原成硼烷,得到对映体纯(3)在Mitsunobu条件下用碳亲核试剂将这些吲哚醇底物的立体选择性S N 2-置换,以设定C 1或C 3叔碳立体中心。使用三甲基膦(PMe 3)和偶氮二羧酸双(2,2,2-三氯乙基)酯(TCEAD)对Mitsunobu脱水烷基化有影响。
Compositions and Methods for Viral Inhibition
申请人:Ni Zhi-Jie
公开号:US20070276009A1
公开(公告)日:2007-11-29
The present invention discloses methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including carbazole derivatives useful for viral inhibition.
Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B)
作者:C Liljebris
DOI:10.1016/s0968-0896(02)00176-1
日期:2002.10
A series of novel pyridazine analogues were prepared and the structure activity relationship of their behavior as inhibitors of PTP1B was evaluated. Most of the analogues had potencies in the low micromolar range. The in vitro kinetics of this compound series demonstrated that they were reversible non-competitive binders. This indicates that there may exist another site in the enzyme through which enzyme activity can be inhibited, which is not a recognized interaction domain. Some of the analogues exhibited high selectivity for other PTPases, for example, compound 12mp showed 20-fold selectivity for PTP1B (IC50 = 5.6 muM) versus both TCPTP and LAR (>100 muM, respectively). In contrast to many tyrosine phosphatase mimetic inhibitors, this compound class lacks negative charge and thus showed high permeability across cell membranes. Selective analogues in the series were analyzed in an in vitro cellular assay, which showed increased insulin-stimulated insulin receptor phosphorylation. (C) 2002 Elsevier Science Ltd. All rights reserved.